
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a top competitor in the regenerative medicine market, offering a diverse portfolio of advanced wound care and sports medicine products. The recent release of 4Q25 financial results and FY26 guidance show strong growth potential, driven by increased demand for their products and high-teens adjusted EBITDA margins. The company's expanding product portfolio and its focus on addressing unmet needs in the market, such as their highly versatile PuraPly product and the upcoming return of Dermagraft, further support a positive outlook for the stock.
Bears say
Organogenesis Holdings is facing negative headwinds in its advanced wound care segment, including slower-than-expected growth in PuraPly, pricing pressures on its amniotic products from Medicare Part B, and challenges from competitors. Additionally, changes to reimbursement structures are leading to confusion and a freeze in product utilization by clinicians, which could negatively impact the company's financials. Despite its potential for growth, the company's outlook is hindered by these fundamental factors.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares